Drugmaker Novo Nordisk to slash some insulin prices by 75% – By Marina Pitofsky (USA Today) / Mar 14, 2023
Novo Nordisk, a Danish drugmaker, announced it will cut some insulin prices in the United States up to 75% next year, amid pressure from competitors and lawmakers.
The drugmaker will lower the list price of multiple insulin brands, including NovoLog and NovoLog Mix 70/30, by 75% of the list price. It will lower the list price of Novolin and Levemir by 65%, Novo Nordisk confirmed Tuesday.
A list price is a price a drugmaker first sets for a product. People with no insurance or people with some health insurance plans sometimes pay the entire fee.
Novo Norodisk’s price cuts will go into effect on Jan. 1. A vial of NovoLog and NovoLog Mix 70/30 will drop to $72.34 from $289.36. And FlexPen options will drop to $139.71 from over $500.
